Continuum Advisory LLC Boosts Holdings in Amgen Inc. (NASDAQ:AMGN)

Continuum Advisory LLC lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 13.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,119 shares of the medical research company’s stock after purchasing an additional 620 shares during the period. Continuum Advisory LLC’s holdings in Amgen were worth $1,515,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Capital Performance Advisors LLP acquired a new stake in Amgen during the third quarter worth approximately $25,000. Strategic Financial Concepts LLC acquired a new stake in Amgen in the 2nd quarter worth about $26,000. Legacy Investment Solutions LLC acquired a new position in shares of Amgen during the 3rd quarter valued at about $29,000. Hershey Financial Advisers LLC purchased a new position in shares of Amgen during the 2nd quarter worth about $30,000. Finally, nVerses Capital LLC acquired a new stake in shares of Amgen in the second quarter worth approximately $31,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

AMGN has been the topic of a number of research analyst reports. Barclays lifted their price target on shares of Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a report on Monday, October 7th. William Blair reissued an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. Redburn Partners decreased their target price on Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Wolfe Research began coverage on shares of Amgen in a report on Friday, November 15th. They issued a “peer perform” rating on the stock. Finally, Leerink Partners dropped their price objective on shares of Amgen from $349.00 to $302.00 in a research report on Wednesday, November 27th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Amgen currently has an average rating of “Hold” and an average target price of $323.05.

Amgen Trading Down 0.6 %

NASDAQ:AMGN opened at $272.58 on Monday. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The company has a market cap of $146.52 billion, a PE ratio of 34.90, a P/E/G ratio of 3.02 and a beta of 0.55. Amgen Inc. has a 52 week low of $257.80 and a 52 week high of $346.85. The business’s 50 day moving average is $306.58 and its two-hundred day moving average is $315.86.

Amgen (NASDAQ:AMGN) last released its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm had revenue of $8.50 billion during the quarter, compared to analyst estimates of $8.50 billion. During the same quarter in the previous year, the firm earned $4.96 earnings per share. The firm’s revenue for the quarter was up 23.2% compared to the same quarter last year. On average, analysts predict that Amgen Inc. will post 19.51 EPS for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be issued a $2.25 dividend. The ex-dividend date of this dividend is Monday, November 18th. This represents a $9.00 dividend on an annualized basis and a yield of 3.30%. Amgen’s dividend payout ratio is currently 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.